Join to View Full Profile
400 E 3RD ST ESSENTIA HEALTH DULUTH CLINICDuluth, MN 55805
Phone+1 218-786-3625
Dr. Millikan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1988 - 1991
University of Miami Leonard M. Miller School of MedicineClass of 1988
Certifications & Licensure
IL State Medical License 2022 - 2026
MN State Medical License 2013 - 2024
WA State Medical License 2020 - 2023
OR State Medical License 2020 - 2022
UT State Medical License 2019 - 2022
TX State Medical License 1994 - 2013
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2008
- America's Top Doctors for Cancer Castle Connolly, 2005-2007
Clinical Trials
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Start of enrollment: 1996 Aug 01
- Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer Start of enrollment: 1997 Dec 01
- Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Start of enrollment: 2001 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsThe combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate...Farshid Dayyani, Amado J. Zurita, Graciela M. Nogueras-Gonzalez, Rebecca Slack, Randall E. Millikan
BMC Cancer. 2016-09-06 - 37 citationsA Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.Arlene O. Siefker-Radtke, Xin Qiao Zhang, Charles C. Guo, Yu Shen, Kathleen F. Pirollo
Molecular Therapy. 2016-08-01 - 216 citationsA Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chem...David J. McConkey, Woonyoung Choi, Yu Shen, I. Ling Lee, Sima P. Porten
European Urology. 2016-05-01
Other
- Experimental systemic therapy of metastatic bladder cancerMillikan RE
http://www.uptodate.com/contents/experimental-systemic-therapy-of-metastatic-bladder-cancer
UpToDate, Wolters Kluwer Health - 2012-09-25
Grant Support
- Neoadjuvant Therapy For Advanced Bladder CancerNational Cancer Institute1996–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
